Halozyme Therapeutics, Inc. (HALO) stock
Close on Nov 17, 2026Market cap $10.89BP/E 28.3Yield –
Halozyme Therapeutics, Inc. grew revenue 41.2% to $1.66B over the twelve months to Jun 30, 2026. Operating income fell 12.5% to $597.20M, moving the operating margin from 57.9% to 35.9%. Free cash flow was $806.22M, up 49.1% from a year earlier. At the latest close the market valued the company at $10.89B, 28.3 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $10.89B
- P/E ratio
- 28.3
- Price to sales
- 6.55
- Price to book
- 75.88
- Dividend yield
- –
- Free cash flow yield
- 7.40%
Fundamentals
- Revenue
- $1.66B
- Net income
- $413.60M
- EPS, diluted
- $3.39
- Free cash flow
- $806.22M
- Book value per share
- $1.18
- Diluted shares
- 121M
Trading
- Next earnings
- Feb 16, 2027 (estimated, after the close)
- Previous close
- $96.50
- Open
- $95.99
- Day's range
- $94.93 – $97.01
- Volume
- 2,041,121
- Average volume (20 days)
- 2,366,894
- Index membership
- S&P MidCap 400 (since Nov 2020), Russell 1000 (since Jun 2025), Russell 3000
- 52-week range
- $61.23 – $134.00
- RSI (14 days)
- 23.8
- Volatility (1 year)
- 41.1%
- Relative volume
- 0.94×
On 1 of our idea list: Buyback cannibals
Index membership is inferred from the holdings of funds that track each index (IJH, SPMD, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | HALO | S&P 500 | Difference | HALO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -21.2% | -4.0% | −17.2 pts | ||
| 3 months | -6.8% | -5.0% | −1.9 pts | ||
| Year to date | +42.6% | +8.2% | +34.4 pts | ||
| 1 year | +36.0% | +11.2% | +24.8 pts | ||
| 3 years | +140.3% | +68.5% | +71.9 pts | +34.0% | +19.0% |
| 5 years | +160.6% | +67.3% | +93.4 pts | +21.1% | +10.8% |
| 10 years | +639.4% | +291.6% | +347.7 pts | +22.1% | +14.6% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Halozyme Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Results
- Results
- Results
About Halozyme Therapeutics
Biological Products, (No Diagnostic Substances)
Halozyme Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes drug delivery platforms and specialized injection devices. The company's core offering is its ENHANZE technology, powered by the proprietary recombinant human hyaluronidase enzyme rHuPH20, which facilitates rapid subcutaneous delivery of injectable biologics and fluids to reduce patient treatment burden. Halozyme also develops the Hypercon and Surf Bio drug concentration technologies, alongside pressure-assisted auto-injectors and multi-dose pens. Its business model spans licensing proprietary delivery platforms to biopharmaceutical partners, collaborative drug-device product development, and the direct commercialization of proprietary offerings such as Hylenex recombinant and XYOSTED. Customers and collaborators include major global pharmaceutical companies, healthcare providers, and patients.
Company profile, executives and historyHalozyme Therapeutics stock: common questions
What is Halozyme Therapeutics's stock price?
HALO closed at $95.97 on Nov 17, 2026, down 0.55% on the day. Over the past 52 weeks it traded between $61.23 and $134.00.
What is Halozyme Therapeutics's market cap?
Halozyme Therapeutics was worth $10.89B at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is HALO's P/E ratio?
HALO trades at 28.3 times earnings, based on diluted earnings per share of $3.39 over the twelve months to Jun 30, 2026.
How much revenue does Halozyme Therapeutics make?
Halozyme Therapeutics reported revenue of $1.66B for the twelve months to Jun 30, 2026, up 41.2% from a year earlier.
Does Halozyme Therapeutics pay a dividend?
No. Halozyme Therapeutics has not paid a cash dividend over the last twelve months.
When does Halozyme Therapeutics report earnings next?
Halozyme Therapeutics is expected to report Q4 FY2026 results on Feb 16, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has HALO stock performed over the past year?
Including dividends, HALO returned +36.0% over the past year, against +11.2% for the S&P 500.
How many HALO shares are sold short?
14M shares were sold short at the latest FINRA report, 12.18% of the float, or 6.8 days of average trading volume.
Who are Halozyme Therapeutics's competitors?
Companies most similar to Halozyme Therapeutics by business, industry and size include BCRX, BNTX, NBIX, MRNA, RGEN.
See a number that looks wrong?